2020
DOI: 10.1111/jphs.12371
|View full text |Cite
|
Sign up to set email alerts
|

Critical Appraisal of the Clinical Practice Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: European Society of Cardiology (ESC) and European Atherosclerosis Society (ESC/EAS) 2019 Guidelines

Abstract: Objective The aim of the study was to assess the quality of the recently published European clinical practice guidelines for the management of dyslipidaemias, utilizing the refined Appraisal of Guidelines for Research & Evaluation tool. Method The 2019 European Society of Cardiology and European Atherosclerosis Society Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk was appraised and scored for methodological rigour and transparency by 5 independent appraisers … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 7 publications
(6 reference statements)
0
1
0
Order By: Relevance
“…The inverse association between plasma high-density lipoprotein and the risk of CVD is among the most consistent and reproducible associations in observational epidemiology. Higher plasma Lp(a) concentrations are associated with an increased risk of CVD, but it appears to be a much weaker risk factor for most people than LDL cholesterol [ 52 ]. Commonly, plasma cholesterol is used to calculate cardiovascular risk, whereas LDL is used to evaluate the achieving of target values according to the estimated cardiovascular risk.…”
Section: Resultsmentioning
confidence: 99%
“…The inverse association between plasma high-density lipoprotein and the risk of CVD is among the most consistent and reproducible associations in observational epidemiology. Higher plasma Lp(a) concentrations are associated with an increased risk of CVD, but it appears to be a much weaker risk factor for most people than LDL cholesterol [ 52 ]. Commonly, plasma cholesterol is used to calculate cardiovascular risk, whereas LDL is used to evaluate the achieving of target values according to the estimated cardiovascular risk.…”
Section: Resultsmentioning
confidence: 99%